Abbott (ABT) Stock Slides as Market Rises: Facts to Know Before You Trade

18.06.24 00:00 Uhr

Werte in diesem Artikel
Aktien

96,19 EUR 0,19 EUR 0,20%

Indizes

PKT PKT

18.398,5 PKT 115,0 PKT 0,63%

15.547,3 PKT 112,8 PKT 0,73%

2.725,8 PKT 12,2 PKT 0,45%

5.615,4 PKT 30,8 PKT 0,55%

The most recent trading session ended with Abbott (ABT) standing at $103.45, reflecting a -0.22% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.77%. Elsewhere, the Dow saw an upswing of 0.49%, while the tech-heavy Nasdaq appreciated by 0.95%.The the stock of maker of infant formula, medical devices and drugs has fallen by 0.39% in the past month, lagging the Medical sector's gain of 1.49% and the S&P 500's gain of 3.71%.The investment community will be paying close attention to the earnings performance of Abbott in its upcoming release. The company is predicted to post an EPS of $1.10, indicating a 1.85% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $10.35 billion, up 3.78% from the year-ago period.For the annual period, the Zacks Consensus Estimates anticipate earnings of $4.62 per share and a revenue of $41.66 billion, signifying shifts of +4.05% and +3.86%, respectively, from the last year.Investors should also note any recent changes to analyst estimates for Abbott. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Right now, Abbott possesses a Zacks Rank of #3 (Hold).From a valuation perspective, Abbott is currently exchanging hands at a Forward P/E ratio of 22.45. For comparison, its industry has an average Forward P/E of 23.95, which means Abbott is trading at a discount to the group.Meanwhile, ABT's PEG ratio is currently 2.49. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. ABT's industry had an average PEG ratio of 2.16 as of yesterday's close.The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 139, finds itself in the bottom 45% echelons of all 250+ industries.The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.Highest Returns for Any Asset ClassIt’s not even close. Despite ups and downs, Bitcoin has been more profitable for investors than any other decentralized, borderless form of money.No guarantees for the future, but in the past three presidential election years, Bitcoin’s returns were as follows: 2012 +272.4%, 2016 +161.1%, and 2020 +302.8%. Zacks predicts another significant surge in months to come.Hurry, Download Special Report – It’s FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Abbott Laboratories

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Abbott Laboratories

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Abbott Laboratories

Analysen zu Abbott Laboratories

DatumRatingAnalyst
27.08.2020Abbott Laboratories SellGoldman Sachs Group Inc.
16.10.2018Abbott Laboratories OverweightBarclays Capital
25.01.2018Abbott Laboratories BuyStifel, Nicolaus & Co., Inc.
15.12.2017Abbott Laboratories OutperformBMO Capital Markets
19.10.2017Abbott Laboratories BuyStifel, Nicolaus & Co., Inc.
DatumRatingAnalyst
16.10.2018Abbott Laboratories OverweightBarclays Capital
25.01.2018Abbott Laboratories BuyStifel, Nicolaus & Co., Inc.
15.12.2017Abbott Laboratories OutperformBMO Capital Markets
19.10.2017Abbott Laboratories BuyStifel, Nicolaus & Co., Inc.
19.10.2017Abbott Laboratories OutperformRBC Capital Markets
DatumRatingAnalyst
23.07.2015Abbott Laboratories Equal WeightBarclays Capital
27.03.2015Abbott Laboratories Equal WeightBarclays Capital
30.01.2015Abbott Laboratories Equal WeightBarclays Capital
07.01.2013Abbott Laboratories haltenDeutsche Bank Securities
29.11.2012Abbott Laboratories neutralSarasin Research
DatumRatingAnalyst
27.08.2020Abbott Laboratories SellGoldman Sachs Group Inc.
25.10.2011Abbott Laboratories sellCitigroup Corp.
05.10.2011Abbott Laboratories sellCitigroup Corp.
22.11.2006Advanced Medical Optics sellCitigroup
11.09.2006Abbott Laboratories reduceUBS

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Abbott Laboratories nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"